1. 15289852 Oncol Rep. (2004)

• This study was conducted to investigate the anti-proliferative activities of medicinal mushroom Ganoderma lucidum (Rei-shi or Mannentake).
• We have identified an alcohol extract from the spore of Ganoderma lucidum that inhibits the in vitro proliferation of human umbilical vein endothelial cells and MDA-MB231 human breast cancer cells.
• Our results suggest that the alcohol extract from the spore of Ganoderma lucidum may possess potential anti-tumor and anti-angiogenic activities.

2. 15169641 Acta Pharmacol Sin. (2004)

• AIM: To investigate the antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide (GLPP).
• To investigate the anti-angiogenic effect of GLPP, GLPP 80 microg per disc and GLPP-treated serum 10 microL per disc were added to the chick chorioallantoic membrane (CAM) respectively in vivo.
• The CAM assay showed that GLPP and GLPP-treated serum had anti-angiogenic effect.
• CONCLUSION: GLPP has antitumor and anti-angiogenic activity.

3. 14698502 J Ethnopharmacol. (2004)

• Fresh fruit bodies of Ganoderma lucidum were extracted with 70% ethanol at room temperature.
• The extract (GL) showed significant anti-angiogenic activity, which was detected using a chick embryo chorioallantoic membrane assay.
• These results support the anti-tumor effect of Ganoderma lucidum.

4. 12596858 Biosci Biotechnol Biochem. (2002) Genes: GCP

• Soybean extracts (SBE) containing isoflavone glycosides were cultured with Ganoderma lucidum mycelia producing beta-glucosidase.
• The anti-angiogenic effects of the cultivated product, containing rich in genistein, named GCP (genistein combined polysaccharide), were assessed with chick chorioallantoic membranes (CAM) and a mouse dorsal air-sac model.